NCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
Clinical Trials
10 trialsNCT05228015 2024-11-18
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT02954523 2024-07-05
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Georgetown University
Phase 1/2 Terminated
NCT04908956 2024-06-28
STEREO
ETOP IBCSG Partners Foundation
Phase 2 Terminated
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03418532 2023-03-23
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
Molecular Partners AG
Phase 1 Terminated
NCT04438902 2023-02-21
Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
First Affiliated Hospital of Zhejiang University
Phase 2 Terminated
NCT03784599 2022-11-10
TRAEMOS
The Netherlands Cancer Institute
Phase 2 Terminated
NCT03255083 2022-01-19
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 1 Terminated